Grace Therapeutics, Inc GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by hydrocarbsson Apr 02, 2020 1:26pm

111 Views

Post# 30872709

RE:RE:RE:Well, each of us should write to express our anger

Until 2016, Ms. D’Alvise was the President and Chairman of Pediatric Bioscience.

Mar 2, 2016		1	Petition Voluntary Petition for Non-Individuals Schedules & Statements Fee Amount $ 335.00. Declaration re: ECF due by 03/16/2016, Filed by Alan Vanderhoff of Vanderhoff Law Group on behalf of Pediatric Bioscience, Inc.. (Vanderhoff, Alan) (Entered: 03/02/2016)